Interactions of mefloquine with praziquantel in the schistosoma mansoni mouse model and in vitro

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 8, 2011, Pages 1791-1797

  Keiser, Jennifer ^a,b   Manneck, Theresia ^a,b   Vargas, Mireille ^a,b  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Activity; Combination chemotherapy; Combination index; Isobolography; Schistosomiasis

Indexed keywords

MEFLOQUINE; PRAZIQUANTEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROTOZOAL ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; IN VITRO STUDY; LC 50; MOUSE; NONHUMAN; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS; SINGLE DRUG DOSE; TREATMENT DURATION;

ADMINISTRATION, ORAL; ANIMALS; ANTHELMINTICS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; MEFLOQUINE; MICE; PRAZIQUANTEL; RODENT DISEASES; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS MANSONI; TREATMENT OUTCOME;

EID: 79960444155     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr178     Document Type: Article

References (25)

1. White N. Antimalarial drug resistance and combination chemotherapy. Philos Trans R Soc Lond B Biol Sci 1999; 354: 739-49.
2. Caminero JA, Sotgiu G, Zumla A et al. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 2010; 10: 621-9.
3. Silvestris N, Maiello E, De Vita F et al. Update on capecitabine alone and in combination regimens in colorectal cancer patients. Cancer Treat Rev 2010; 36: S46-55.
4. Cui L, Su XZ. Discovery, mechanisms of action and combination therapy of artemisinin. Expert Rev Anti Infect Ther 2009; 7: 999-1013.
5. Utzinger J, Keiser J, Xiao SH et al. Combination chemotherapy of schistosomiasis in laboratory studies and clinical trials. Antimicrob Agents Chemother 2003; 47: 1487-95.
6. Keiser J, Utzinger J. Advances in the discovery and development of novel trematocidal drugs. Expert Opin Drug Discov 2007; 2: 9-23.
7. Kamel G, Metwally A, Guirguis F et al. Effect of a combination of the new antischistosomal drug Ro 15-5458 and praziquantel on different strains of Schistosoma mansoni infected mice. Arzneimittelforschung 2000; 50: 391-4.
8. Keiser J, Vargas M, Vennerstrom JL. Activity of antiandrogens against juvenile and adult Schistosoma mansoni in mice. J Antimicrob Chemother 2010; 65: 1991-5.
9. Hughes JP, Rees S, Kalindjian SB et al. Principles of early drug discovery. Br J Pharmacol 2010; 162: 1239-49.
10. Keiser J, Chollet J, Xiao SH et al. Mefloquine-an aminoalcohol with promising antischistosomal properties in mice. PLoS Negl Trop Dis 2009; 3: e350.
11. Keiser J, N'Guessan NA, Adoubryn KD et al. Efficacy and safety of mefloquine, artesunate, mefloquine-artesunate, and praziquantel against Schistosoma haematobium: randomized, exploratory open-label trial. Clin Infect Dis 2010; 50: 1205-13.
12. Xiao SH, Mei JY, Jiao PY. Effect of mefloquine administered orally at single, multiple, or combined with artemether, artesunate, or praziquantel in treatment of mice infected with Schistosoma japonicum. Parasitol Res 2011; 108: 399-406.
13. Chou TC. Drug combinations: from laboratory to practice. J Lab Clin Med 1998; 132: 6-8.
14. Keiser J. In vitro and in vivo trematode models for chemotherapeutic studies. Parasitology 2010; 137: 589-603.
15. Rozman RS, Molek NA, Koby R. The absorption, distribution, and excretion in mice of the antimalarial mefloquine, erythro-2,8-bis(trifluoromethyl)-alpha-(2-piperidyl)-4-quinolinemethanol hydrochloride. Drug Metab Dispos 1978; 6: 654-8.
16. Botros S, El-Lakkany N, Seif El-Din SH et al. Comparative efficacy and bioavailability of different praziquantel brands. Exp Parasitol 2011; 127: 515-21.
17. Manneck T, Braissant O, Ellis W et al. Schistosoma mansoni: antischistosomal activity of the four optical isomers and the two racemates of mefloquine on schistosomula and adult worms in vitro and in vivo. Exp Parasitol 2011; 127: 260-9.
18. Caffrey CR. Chemotherapy of schistosomiasis: present and future. Curr Opin Chem Biol 2007; 11: 433-9.
19. Melman SD, Steinauer ML, Cunningham C et al. Reduced susceptibility to praziquantel among naturally occurring Kenyan isolates of Schistosoma mansoni. PLoS Negl Trop Dis 2009; 3: e504.
20. Mayer LD, Janoff AS. Optimizing combination chemotherapy by controlling drug ratios. Mol Interv 2007; 7: 216-23.
21. Doenhoff MJ, Cioli D, Utzinger J. Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr Opin Infect Dis 2008; 21: 659-67.
22. Aragon AD, Imani RA, Blackburn VR et al. Towards an understanding of the mechanism of action of praziquantel. Mol Biochem Parasitol 2009; 164: 57-65.
23. Manneck T, Haggenmüller Y, Keiser J. Morphological effects and tegumental alterations induced by mefloquine on schistosomula and adult flukes of Schistosoma mansoni. Parasitology 2010; 137: 85-98.
24. Lauritsen KJ, Nguyen T. Combination products regulation at the FDA. Clin Pharmacol Ther 2009; 85: 468-70.
25. Utzinger J, Xiao SH, N'Goran EK et al. The potential of artemether for the control of schistosomiasis. Int J Parasitol 2001; 31: 1549-62.